NCO-48 fumarate
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 18, 2020 (NCT04309526)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04629976 | Phase 1 | Dec 31, 2020 | Ligand Pharmaceuticals, Nucorion Pharmaceuticals, Inc. |
| NCT04309526 | Phase 1 | Mar 18, 2020 | Ligand Pharmaceuticals, Medpace, Inc., Nucorion Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals | For profit | 2 | 0 | 1 | 2020 |
| Nucorion Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2020 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1